Evergreening in action: strategic patent filing Evergreening is not new
Because GLP-1s can impact how your digestive system works, they often cause a few gastrointestinal (GI) side effects
Review article: GLP-1 receptor agonists and glucagon/GIP/GLP-1 receptor dual or triple agonists-mechanism of action and emerging therapeutic landscape in MASLD
I've seen amazing results and feel healthier and more confident than ever
But for women managing chronic migraine alongside obesity or metabolic conditions, this is a clinically meaningful overlap worth raising with a provider

Current and resolved drug shortages and discontinuations reported to the FDA, Food and Drug Administration (2024) Regulatory framework for compounded preparations, National Academies Press (2020) Clinical and legal considerations in pharmaceutical compounding, The Journal of Clinical and Aesthetic Dermatology (2023) FDA alerts health care providers, compounders, and patients of dosing errors associated with compounded injectable semaglutide products, Food and Drug Administration (2024) Medications containing semaglutide marketed for Type 2 diabetes or weight loss, Food and Drug Administration (2024) FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, Food and Drug Administration (2025) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice